Collot et al. profile tumor and immune interactions in DMG.
They identify DMG tumor cells that communicate with microglia through IGSF11-VISTA signaling. Targeting this communication pathway leads to tumor control by microglia and a favorable disease outcome.
This positions IGS11-VISTA as a promising brain-specific therapeutic axis for DMG treatment.
Cancer Cell published a clinical update in Oncology on 22 Jan 2026.
The item focuses on IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma.
Review the original article for the full source wording and details.